CN103462969A - Incarviatone A在治疗乳腺癌药物中的应用 - Google Patents
Incarviatone A在治疗乳腺癌药物中的应用 Download PDFInfo
- Publication number
- CN103462969A CN103462969A CN2013104327592A CN201310432759A CN103462969A CN 103462969 A CN103462969 A CN 103462969A CN 2013104327592 A CN2013104327592 A CN 2013104327592A CN 201310432759 A CN201310432759 A CN 201310432759A CN 103462969 A CN103462969 A CN 103462969A
- Authority
- CN
- China
- Prior art keywords
- incarviatone
- breast cancer
- medicaments
- application
- mcf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 25
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001121991 Incarvillea delavayi Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- TVDHAPBZUYFOQK-NKXJSCLBSA-N C[C@@H](C1)[C@@]1([C@]1(C2OCC1)O)O[C@H]([C@@](C)([C@H](C)CC1=CC(C3)C(CC[C@H]4C)=C4C=O)C1=C3[C@@H]1O)[C@]21O Chemical compound C[C@@H](C1)[C@@]1([C@]1(C2OCC1)O)O[C@H]([C@@](C)([C@H](C)CC1=CC(C3)C(CC[C@H]4C)=C4C=O)C1=C3[C@@H]1O)[C@]21O TVDHAPBZUYFOQK-NKXJSCLBSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310432759.2A CN103462969B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗乳腺癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310432759.2A CN103462969B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗乳腺癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103462969A true CN103462969A (zh) | 2013-12-25 |
CN103462969B CN103462969B (zh) | 2015-12-02 |
Family
ID=49788167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310432759.2A Expired - Fee Related CN103462969B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗乳腺癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103462969B (zh) |
-
2013
- 2013-09-22 CN CN201310432759.2A patent/CN103462969B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
YUN-HENG SHEN等: "Incarviatone A, a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi, and its absolute configuration via calculated electronic circular dichroic spectra", 《RSC ADV.》 * |
Also Published As
Publication number | Publication date |
---|---|
CN103462969B (zh) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103462960A (zh) | Incarviatone A在治疗前列腺癌药物中的应用 | |
CN103405418A (zh) | Chukrasone B在治疗乳腺癌药物中的应用 | |
CN102895224A (zh) | Aphanamixoid A在治疗乳腺癌药物中的应用 | |
CN102872110B (zh) | Houttuynoid D在制备治疗乳腺癌药物中的应用 | |
CN102872085B (zh) | Houttuynoid A在治疗乳腺癌药物中的应用 | |
CN102885843B (zh) | Houttuynoid B在治疗乳腺癌药物中的应用 | |
CN102872075A (zh) | Houttuynoid E在治疗乳腺癌药物中的应用 | |
CN103462969A (zh) | Incarviatone A在治疗乳腺癌药物中的应用 | |
CN103462958A (zh) | Incarviatone A在治疗舌癌药物中的应用 | |
CN103462961A (zh) | Incarviatone A在治疗膀胱癌药物中的应用 | |
CN103462971A (zh) | Incarviatone A在治疗肾癌药物中的应用 | |
CN103462974A (zh) | Incarviatone A在治疗卵巢癌药物中的应用 | |
CN103446088A (zh) | Incarviatone A在治疗皮肤癌药物中的应用 | |
CN103463049A (zh) | Lycojaponicumin B在治疗乳腺癌药物中的应用 | |
CN103446091A (zh) | Incarviatone A在治疗喉癌药物中的应用 | |
CN103356553A (zh) | Sarcaboside A在治疗乳腺癌药物中的应用 | |
CN103462966A (zh) | Incarviatone A在治疗结直肠癌药物中的应用 | |
CN103446089A (zh) | Incarviatone A在治疗鼻咽癌药物中的应用 | |
CN103479630A (zh) | Lycojaponicumin A在治疗乳腺癌药物中的应用 | |
CN103356532A (zh) | Sarcaboside B在治疗乳腺癌药物中的应用 | |
CN103446092A (zh) | Incarviatone A在治疗宫颈癌药物中的应用 | |
CN103463070A (zh) | Lycojaponicumin C在治疗乳腺癌药物中的应用 | |
CN103432116A (zh) | Chukrasone B在治疗舌癌药物中的应用 | |
CN103405449A (zh) | Chukrasone A在治疗乳腺癌药物中的应用 | |
CN103446087A (zh) | Incarviatone A在治疗子宫内膜癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Kong Fanhua Inventor before: Jiang Chunping Inventor before: Huang Rong |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151105 Address after: 272001 Shandong city of Jining province Guhuai Road No. 79 (Affiliated Hospital of Jining Medical College Department) Applicant after: Kong Fanhua Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151202 Termination date: 20160922 |
|
CF01 | Termination of patent right due to non-payment of annual fee |